Long-term effect of neutralizing antibodies to interferon beta-1 b in patients with multiple sclerosis;Efecto a largo plazo de los anticuerpos neutralizantes de interferón beta-1 b en pacientes con esclerosis múltiple

Medicina Clinica

Volumn 124, Issue 4, 2005, Pages 140-141

  Río, Jordi ^a   Tintoré, Mar ^a   Téllez, Nieves ^a   Nos, Carlos ^a   Galán, Ingrid ^a   Montalbán, Xavier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Interferon beta; Multiple sclerosis; Neutralizing antibodies

Indexed keywords

INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PROSPECTIVE STUDY; RELAPSE;

EID: 14744286113     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13071005     Document Type: Article

References (9)

1. IFNB Multiple Sclerosis Study Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1 b: experience during the first three years. Neurology. 1996;47:889-94.
2. Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet. 2003;362:1184-91.
3. Río J, Barberà N, Tintoré M, Brieva L, Montalban X. Anticuerpos neutralizantes en pacientes con esclerosis múltiple tratados con interferón beta-1 b. Med Clin (Barc). 2000;114:169-70.
4. Polman C, Kappos L, White R, Dahlke F, Beckmann K, Pozilli C, et al. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1 b. Neurology. 2003;60:37-43.
5. Giovannoni G, Munschauer FE, Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2002;73:465-9.
6. Rice GP, Paszner B, Oger J, Lesaux J, Paty D, Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1 b. Neurology. 1999;52:1277-9.
7. Pozzilli C, Antonini G, Bagnato F, Mainero C, Tomassini V, Onesti E, et al. Monthly corticosteroids decrease neutralizing antibodies to IFNbeta-1 b: a randomized trial in multiple sclerosis. J Neurol. 2002;249:50-6.
8. Petkau AJ. Statistical approaches to assessing the effects of neutralizing antibodies: IFN-beta-1 b in the pivotal trial of relapsing-remitting multiple sclerosis. Neurology. 2003;61 Suppl 5:35-7.
9. Cutter G. Statistical issues in neutralizing antibodies. Neurology. 2003;61 Suppl 5:38-9.